Nilotinib-d6

• UNSPSC Description:

  Nilotinib-d6 is a deuterium labeled Nilotinib. Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity[1].

• Target Antigen:

  Autophagy; Bcr-Abl

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Autophagy;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Purity:

  99.95

• Solubility:

  DMSO : 125 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)C3=C([2H])C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C(C([2H])([2H])[2H])C([2H])=C3[2H]

• Molecular Weight:

  535.55

• References & Citations:

  [1]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1268356-17-7